Anavex Life Sciences (AVXL) Change in Account Payables (2018 - 2025)
Anavex Life Sciences (AVXL) reported Change in Account Payables of -$1.6 million for Q4 2025, up 68.18% on a YoY basis from -$957297.3 in Q4 2024, and up 35.37% sequentially from -$2.5 million in Q3 2025.
Anavex Life Sciences (AVXL) Change in Account Payables (2018 - 2025) Analysis & Trends
Anavex Life Sciences (AVXL) has 8 years of Change in Account Payables data on file, last reported at -$1.6 million in Q4 2025.
- For the quarter ending Q4 2025, Change in Account Payables rose 68.18% year-over-year to -$1.6 million; the trailing twelve-month figure through Dec 2025 stood at -$1.9 million (down 801.09% YoY), and the FY2025 full-year result was -$5.4 million, down 201.38% from the prior year.
- Change in Account Payables grew to -$1.6 million in Q4 2025, from -$2.5 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $6.1 million in Q3 2024 to a low of -$5.1 million in Q4 2024.
- A 5-year average of -$78844.7 and a median of $68500.0 in 2023 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables jumped 6265.5% in 2021 and sank 16766.67% in 2024, its largest moves.
- Tracing AVXL's Change in Account Payables over 5 years: stood at -$104992.0 in 2021, then jumped by 1493.44% to $1.5 million in 2022, then slumped by 102.05% to -$30000.0 in 2023, then slumped by 16766.67% to -$5.1 million in 2024, then soared by 68.18% to -$1.6 million in 2025.
- Business Quant data shows AVXL's Change in Account Payables at -$1.6 million in Q4 2025, -$2.5 million in Q3 2025, and $2.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Anavex Life Sciences | 229.83 Mn | 98.08 Mn | - | -1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.61 Mn |
| Dec 31, 2025 | -1.61 Mn |
| Sep 30, 2025 | -2.49 Mn |
| Sep 30, 2025 | -2.49 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Jun 30, 2025 | 2.01 Mn |
| Mar 31, 2025 | 167,000.00 |
| Mar 31, 2025 | 167,000.00 |
| Dec 31, 2024 | -5.06 Mn |
| Dec 31, 2024 | -5.06 Mn |
| Sep 30, 2024 | 6.07 Mn |
| Sep 30, 2024 | 6.07 Mn |
| Jun 30, 2024 | -164,000.00 |
| Jun 30, 2024 | -164,000.00 |
| Mar 31, 2024 | -566,000.00 |
| Mar 31, 2024 | -566,000.00 |
| Dec 31, 2023 | -30,000.00 |
| Dec 31, 2023 | -30,000.00 |
| Sep 30, 2023 | 170,000.00 |
| Sep 30, 2023 | 170,000.00 |